ADMA
ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.
ADMA Biologics, Inc. (ADMA) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (3.1) | C (2.5) | B+ (3.7) | B+ (3.5) | C+ (2.6) | B- (3.1) |
| 2026-11-10 | B- (3.1) | C (2.4) | B+ (3.7) | B+ (3.5) | C+ (2.6) | B- (3.1) |
| 2026-11-03 | B- (3.1) | C (2.2) | B+ (3.6) | B- (2.9) | C+ (2.7) | B- (2.9) |
| 2026-10-27 | B- (3.1) | C (2.2) | B+ (3.6) | C+ (2.7) | C+ (2.6) | B- (2.9) |
| 2026-10-20 | B- (3.1) | C (2.2) | B+ (3.6) | C+ (2.7) | C+ (2.6) | B- (2.9) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe